Reviewer’s report

Title: Case report: Ocular toxicity due to Trametinib and Dabrafenib

Version: 1 Date: 30 Jun 2017

Reviewer: Simon Taylor

Reviewer's report:

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

This is an interesting case report with good illustrations (especially the ICGA). These drugs are becoming more common, so knowledge of their ocular side-effects is important. Minor English language editing is required throughout. My major criticism is that the authors need to think about what they are recommending - this patient's uveitis was symptomatic and was reversible with cessation of therapy/topical steroids, so why is screening required? They present no evidence of asymptomatic ocular pathology that would be better treated with early therapy, so there is no evidence here to support the institution of a screening programme for these patients. Surely one could simply tell patients that they may get a reduction in vision and provide a pathway for them to access if they do?

Also, does treatment have to be stopped if there are side-effects (P5L13)? What if it's just anterior uveitis which can be well-controlled with topical steroids. Wouldn't these patients be better treated with a potentially life-saving drug for their melanoma and just continuing to take the topical steroids, rather than stopping the drug? I do think the authors need to be careful about making sweeping statements based on their one case here.

A couple of small things where the text does not make sense, e.g.

P4L7 - 'prevents the T-cells from inactivity'? - meaning what exactly?

P4L16 - 'visual loss of 10%'? - measured how?
Are the methods appropriate and well described?  
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?  
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?  
If not, please explain in your comments to the authors.

No

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?  
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

Not relevant to this manuscript

Quality of written English  
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

Declaration of competing interests  
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal